Table 1. Patient characteristics at the time of signing the informed consent form (inclusion).
| Variables | 182 Cases | 182 Controls | |
|---|---|---|---|
| n (%) or Median [Q1-Q3] | |||
| Demographic characteristics | |||
| Male | 107 (59) | 98 (54) | |
| Age, yrs | 57 [48–64] | 55 [47–63] | |
| Referred from outside the cancer center | 105 (58) | 83 (46) | |
| ECOG PS 0 | 59 (32) | 85 (47) | |
| 1 | 112 (62) | 93 (51) | |
| Distance home-cancer center (km) | 69 [20–397] | 55 [19–241] | |
| Number of medications | 3 [2–5] | 2 [0–3] | |
| Tumor characteristics | |||
| Primary tumor site | |||
| lung | 34 (19) | 34 (19) | |
| colorectal | 23 (13) | 27 (16) | |
| melanoma | 18 (10) | 16 (9) | |
| breast | 16 (9) | 18 (11) | |
| prostate | 15 (8) | 9 (5) | |
| Metastatic site | |||
| liver | 80 (44) | 74 (41) | |
| brain | 27 (15) | 3 (2) | |
| bone | 62 (34) | 38 (21) | |
| peritoneum | 21 (12) | 9 (5) | |
| Number of previous lines | 3 [2–4] | 3 [1–4] | |
| Duration of PFS after previous line (weeks) | 12 [9–18] | 14 [10–30] | |
| Poor prognostic RMH score (≥2) | 75 (41) | 58 (32) | |
| Phase 1 clinical trial characteristics | |||
| Wash-out (days) | 56 [36–85] | 56 [35–164] | |
| Time between inclusion and C1D1 (days) | 14 [9–22] | 11 [7–16] | |
| Previous inclusion in a P1 trial | 23 (13) | 19 (10) | |
| Further offer to participate in a P1 trial | 17 (9) | 52 (29) | |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; P1, phase 1; RMH, Royal-Marsden Hospital; C1D1, Cycle 1 day 1.